Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$525.28 USD

525.28
842,078

-0.66 (-0.13%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

5 Cash Cow Stocks to Buy Now

by Sweta Killa

Procter & Gamble (PG), Amazon (AMZN), Verizon (VZ), McKesson (MCK) and D.R. Horton (DHI) are some of the cash-rich companies that one can invest in.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

by Zacks Equity Research

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Cencora (COR) Stock for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Retain DexCom (DXCM) Stock for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Sumit Singh headshot

Add These 4 Stocks With Remarkable Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. STRL, SFM, MOH and MCK are sound enough to meet financial obligations.

Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems

by Zacks Equity Research

Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.

DexCom (DXCM) Rises 7% in One Week: What's Driving It?

by Zacks Equity Research

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Should Value Investors Buy McKesson (MCK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why McKesson (MCK) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services

by Zacks Equity Research

Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

Revvity (RVTY) Launches Three New Preclinical Research Systems

by Zacks Equity Research

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.

Are Medical Stocks Lagging McKesson (MCK) This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany

by Zacks Equity Research

DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.

NextGen's (NXGN) Shares Rise on Potential Acquisition Rumors

by Zacks Equity Research

NextGen (NXGN) and a private equity firm, Thomas Bravo, are in advanced stages of discussion related to the acquisition of the former by the latter.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Phibro (PAHC) Q4 Earnings Miss Estimates, Gross Margin Falls

by Zacks Equity Research

Robust performance across the Animal Health segment is encouraging for Phirbo (PAHC).

Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?

by Zacks Equity Research

Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?

Cardinal Health's (CAH) Latest Launch to Enhance Neonatal Feeding

by Zacks Equity Research

Cardinal Health's (CAH) latest offering is likely to help premature and newborn infants develop the oral coordination skills important for the faster transition to independent feeding.